Last reviewed · How we verify
hypoxia-activated prodrug TH-302 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
hypoxia-activated prodrug TH-302 (hypoxia-activated prodrug TH-302) — Alliance for Clinical Trials in Oncology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| hypoxia-activated prodrug TH-302 TARGET | hypoxia-activated prodrug TH-302 | Alliance for Clinical Trials in Oncology | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- hypoxia-activated prodrug TH-302 CI watch — RSS
- hypoxia-activated prodrug TH-302 CI watch — Atom
- hypoxia-activated prodrug TH-302 CI watch — JSON
- hypoxia-activated prodrug TH-302 alone — RSS
Cite this brief
Drug Landscape (2026). hypoxia-activated prodrug TH-302 — Competitive Intelligence Brief. https://druglandscape.com/ci/hypoxia-activated-prodrug-th-302. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab